In situ breast cancer

Breast Cancer Epidemiology

Volumn , Issue , 2010, Pages 47-72

  Sprague, Brian L ^a,b   Trentham Dietz, Amy ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649323313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0685-4_3     Document Type: Chapter

References (142)

1. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ (2001) Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115:85-98
2. Adem C, Reynolds C, Soderberg CL et al (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97:1-11
3. Alpers CE, Wellings SR (1985) The prevalence of carcinoma in situ in normal and cancerassociated breasts. Hum Pathol 16:796-807
4. Barchielli A, Paci E, Giorgi D (1999) Recent trends of in situ carcinoma of the breast and mammographic screening in the Florence area, Italy. Cancer Causes Control 10:313-317
5. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-Term follow-up after treatment by biopsy alone. JAMA 239:1863-1867
6. Bijker N, Peterse JL, Duchateau L et al (2001) Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539-544
7. Boyages J, Delaney G, TaylorR (1999) Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-Analysis. Cancer 85:616-628
8. Boyd NF, Jensen HM, Cooke G, Han HL (1992) Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 84:1170-1179
9. Boyd NF, Rommens JM, Vogt K et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798-808
10. Brinton LA, Daling JR, Liff JM et al (1995) Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87:827-835
11. Brinton LA, Hoover R, Fraumeni JF Jr (1983) Epidemiology of minimal breast cancer. JAMA 249:483-487
12. Brinton LA, Hoover R, Fraumeni JF Jr (1986) Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 54:825-832
13. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441
14. Chuba PJ, Hamre MR, Yap J et al (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534-5541
15. Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964-969
16. Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: Risk factors and screening patterns. J Natl Cancer Inst 93:1811-1817
17. Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Br Cancer Res Treat 78:7-15
18. Claus EB, Stowe M, Carter D (2003) Oral contraceptives and the risk of ductal breast carcinoma in situ. Br Cancer Res Treat 81:129-136
19. Colditz GA (2007) Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus progestin. Br Cancer Res 9:108
20. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87:1234-1245
21. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059
22. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713-1727
23. Collins LC, Connolly JL, Page DL et al (2004) Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: Results from a randomized clinical trial. Am J Surg Pathol 28:126-131
24. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses' Health Study. Cancer 103:1778-1784
25. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B et al (2001) Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37:2365-2372
26. Dallal CM, Sullivan-Halley J, Ross RK et al (2007) Long-Term recreational physical activity and risk of invasive and in situ breast cancer: The California teachers study. Arch Intern Med 167:408-415
27. Damiani S, Eusebi V (2002) Gross and microscopic pathology. In: Donegan WL, Spratt JS, eds. Cancer of the breast, 5th edn. Saunders, Philadelphia, pp 347-375
28. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151
29. Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616
30. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913-918
31. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953-958
32. Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma. J Natl Cancer Inst Monogr: 151-156
33. Eusebi V, Feudale E, Foschini MP et al (1994) Long-Term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11:223-235
34. FeigelsonHS, Jonas CR, Robertson AS, McCulloughML, ThunMJ, Calle EE (2003)Alcohol, folate,methionine, and risk of incident breast cancer in theAmerican Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 12:161-164
35. Fisher B, Costantino J, Redmond C et al (1993) Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581-1586
36. Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452
37. Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000
38. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28:400-418
39. Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma. Cancer 86:429-438
40. Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Twelve-year observations concerning lobular carcinoma in situ. Cancer 100:238-244
41. Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B (1991) Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol 47:139-147
42. Friedenreich CM (2001) Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10:15-32
43. Gammon MD, Santella RM, Neugut AI et al (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677-685
44. Gammon MD, Schoenberg JB, Teitelbaum SL et al (1998) Cigarette smoking and breast cancer risk among young women (United States). Cancer Causes Control 9:583-590
45. Gammon MD, Wolff MS, Neugut AI et al (2002) Environmental toxins and breast cancer on Long Island. II. Organochlorine compound levels in blood. Cancer Epidemiol Biomarkers Prev 11:686-697
46. Gandini S, Merzenich H, Robertson C, Boyle P (2000) Meta-Analysis of studies on breast cancer risk and diet: The role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 36:636-646
47. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study. JAMA 281:2091-2097
48. Gill JK, Maskarinec G, Pagano I, Kolonel LN (2006) The association of mammographic density with ductal carcinoma in situ of the breast: The Multiethnic Cohort. Br Cancer Res 8:R30
49. Gill JK, Press MF, Patel AV, Bernstein L (2006) Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 17:1155-1162
50. Goldschmidt RA, Victor TA (1996) Lobular carcinoma in situ of the breast. Semin Surg Oncol 12:314-320
51. Gorski B, Narod SA, Lubinski J (2005) Acommon missense variant in BRCA2 predisposes to early onset breast cancer. Br Cancer Res 7:R1023-R1027
52. Haagenson C (1986) Lobular neoplasia (lobular carcinoma in situ). In: Haagenson C (ed) Diseases of the breast. Saunders, Philadelphia
53. Habel LA, Daling JR, Newcomb PA et al (1998) Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 7:689-696
54. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS (1997) Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225:69-75
55. Hankinson SE, Colditz GA, WillettWC (2004) Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Br Cancer Res 6:213-218
56. Hankinson SE, Hunter D (2002) Breast cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 301-339
57. Harris J, Morrow M, Norton L (1997) Malignant tumors of the breast. In: Devita VT, Jr, Hellman S, Rosenberg SA (eds). Cancer principles & practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 1557-1616
58. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51:1277-1283
59. Humphrey LL, Helfand M, Chan BK, Woolf SH (2002) Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:347-360
60. Hunter DJ, Spiegelman D, Adami HO et al (1996) Cohort studies of fat intake and the risk of breast cancer-A pooled analysis. N Engl J Med 334:356-361
61. Hwang ES, Esserman LJ (1999) Management of ductal carcinoma in situ. Surg Clin North Am 79:1007-1030, viii
62. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25:642-647
63. IARC (2002) IARC handbooks on cancer prevention, Vol. 6: Weight control and physical activity. IARC Press, Lyon, France
64. Jacobs EJ, Feigelson HS, Bain EB et al (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Br Cancer Res 8:R22
65. Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Br Cancer Res 9:R28
66. Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355:528-533
67. Kauff ND, Brogi E, Scheuer L et al (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97:1601-1608
68. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V (1997) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89:76-82
69. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA (2007) Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99:1335-1339
70. Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95:1692-1702
71. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646
72. Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-1145
73. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO (1998) Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J Cancer 77:330-332
74. Lerwill MF (2004) Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 28:1076-1091
75. Levi F, Randimbison L, Te VC, La Vecchia C (2005) Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer 116:820-823
76. Levi F, Te VC, Randimbison L, La Vecchia C (1997) Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 33:903-906
77. Li CI, Daling JR (2007) Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773-2780
78. Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 106:2104-2112
79. Lipworth L, Bailey LR, Trichopoulos D (2000) History of breast-feeding in relation to breast cancer risk: A review of the epidemiologic literature. J Natl Cancer Inst 92:302-312
80. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5:961-965
81. Luke C, Priest K, RoderD(2006) Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening. Asian Pac J Cancer Prev 7:69-74
82. MacKenzie TA, Titus-Ernstoff L, Vacek PM et al (2007) Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control 18:939-945
83. McCarthy EP, Burns RB, FreundKMet al (2000) Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 48:1226-1233
84. McTiernan A (2003) Behavioral risk factors in breast cancer: Can risk be modified? Oncologist 8:326-334
85. Meeske K, Press M, Patel A, Bernstein L (2004) Impact of reproductive factors and lactation on breast carcinoma in situ risk. Int J Cancer 110:102-109
86. Millikan R, Eaton A, Worley K et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Br Cancer Res Treat 79:355-364
87. Millikan RC, Player J, De Cotret AR et al (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Br Cancer Res 6:R264-R274
88. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856-1865
89. Mohsin SK O'Connell P, Allred DC, Libby AL (2005) Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Br Cancer Res Treat 90:249-256
90. Mommers EC, Leonhart AM, Falix F et al (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194:327-333
91. Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, Van Diest PJ (2001) Nuclear cytometric changes in breast carcinogenesis. J Pathol 193:33-39
92. Nasca PC, Liu S, Baptiste MS, Kwon CS, Jacobson H, Metzger BB (1994) Alcohol consumption and breast cancer: Estrogen receptor status and histology. Am J Epidemiol 140:980-988
93. National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V.2.2007. Available at www.nccn.org/professionals/physician-gls/ PDF/breast.pdf 2007
94. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2007) Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16:2262-2268
95. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA (1987) Breast cancer and atypia among young and middle-Aged women: A study of 110 medicolegal autopsies. Br J Cancer 56:814-819
96. Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 49:751-758
97. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW(1991) Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232-1239
98. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: A retrospective cohort study. Lancet 361:125-129
99. Patel AV, Press MF, Meeske K, Calle EE, Bernstein L (2003) Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer 98:2161-2169
100. Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943-949
101. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17-35
102. Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773-1783
103. Posner MC, Wolmark N (1992) Non-invasive breast carcinoma. Br Cancer Res Treat 21:155-164
104. Potischman N, Coates RJ, Swanson CA et al (2002) Increased risk of early-stage breast cancer related to consumption of sweet foods among women less than age 45 in the United States. Cancer Causes Control 13:937-946
105. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674
106. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: A cohort study and meta-Analysis. Lancet Oncol 7:910-918
107. Reinier KS, Vacek PM, Geller BM (2007) Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre-And post-menopausal women. Br Cancer Res Treat 103:343-348
108. Rich-Edwards JW, Goldman MB, Willett WC et al (1994) Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 171:171-177
109. Ries LAG, Melbert D, Krapcho M et al (2008) SEER cancer statistics review, 1975-2005. National Cancer Institute, Bethesda. http://seer.cancer.gov/ csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site
110. Rosen P, Snyder RE, Foote FW, Wallace T (1970) Detection of occult carcinoma in the apparently benign breast biopsy through specimen radiography. Cancer 26:944-952
111. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332
112. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333
113. Sasson AR, Fowble B, Hanlon AL et al (2001) Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer 91:1862-1869
114. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN (1994) Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5:491-500
115. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491
116. Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311-1321
117. Schnitt SJ, MorrowM(1999) Lobular carcinoma in situ: Current concepts and controversies. Semin Diagn Pathol 16:209-223
118. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI (2000) Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer 88:946-954
119. Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 45:277-282
120. Solin LJ, Fourquet A, Vicini FA et al (2005) Long-Term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103:1137-1146
121. Solin LJ, Fourquet A, Vicini FA et al (2001) Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: Long-Term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 50:991-1002
122. Sprague BL, Trentham-Dietz A, Garcia-Closas M et al (2007) Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis 28:1680-1686
123. Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton JM, Egan KM (2007) Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16:236-243
124. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-Aged women. JAMA 274:137-142
125. Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647-1657
126. Sun CC, Lenoir G, Lynch H, Narod SA (1996) In-situ breast cancer and BRCA1. Lancet 348:408
127. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Regs Limited-Use, Nov 2007 Sub (1973-2005)-Linked to County Attributes-Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission (www.seer.cancer.gov
128. Swanson CA, Coates RJ, Schoenberg JB et al (1996) Body size and breast cancer risk among women under age 45 years. Am J Epidemiol 143:698-706
129. Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529-1531
130. Terry MB, Zhang FF, Kabat G et al (2006) Lifetime alcohol intake and breast cancer risk. Ann Epidemiol 16:230-240
131. Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9:697-703
132. Trentham-Dietz A, Nichols HB, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA (2007) Cigarette smoking and risk of breast carcinoma in situ. Epidemiology 18:629-638
133. Ursin G, Hovanessian-Larsen L, Parisky YR, Pike MC, Wu AH (2005) Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Br Cancer Res 7:R605-R608
134. Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinomain-situ of the breast: A critical review of the literature. J Clin Oncol 20:2736-2744
135. Warnberg F, Nordgren H, Bergkvist L, Holmberg L (2001) Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 85:869-874
136. Warnberg F, Yuen J, Holmberg L (2000) Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355:724-725
137. Weiss HA, Brinton LA, Brogan D et al (1996) Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 73:1298-1305
138. Welch HG, Black WC (1997) Using autopsy series to estimate the disease ''reservoir'' for ductal carcinoma in situ of the breast: How much more breast cancer can we find?. Ann Intern Med 127:1023-1028
139. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39:1746-1754
140. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds) (2001) SEER summary stage manual-2000: Codes and coding instructions. National Cancer Institute, Bethesda. NIH Pub. No. 01-4969
141. Zagouri F, Sergentanis TN, Zografos GC (2007) Precursors and preinvasive lesions of the breast: The role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol 5:57
142. Zeleniuch-Jacquotte A, Gu Y, Shore RE et al (2005) Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: Results of a prospective study. Int J Cancer 114:323-327